{"entity":{"id":"stem-cell-mobilisation-and-collection","kind":"protocol","name":"Peripheral blood stem cell mobilisation and collection for transplant, in patients and donors","aka":["stem cell harvest","stem cell collection","PBSC mobilisation","PBSC collection","stem cell mobilization","leukapheresis for stem cells","G-CSF mobilisation","plerixafor","just-in-time plerixafor","poor mobiliser","CD34 target","peripheral blood stem cell donation","donating stem cells"],"tldr":"Stem cells for a transplant are usually collected from the blood rather than the bone marrow. Daily injections of a growth factor for about four to five days move stem cells out of the marrow into the blood, and a machine then filters them out over a few hours while the rest of the blood is returned. If too few cells appear in the blood, a second medicine called plerixafor can be added.","summary":"The reader's own unit's policy comes first. Patients (autologous): G-CSF alone ('steady state', filgrastim 10 micrograms/kg/day under the skin, apheresis usually on day 5) for those needing no further chemotherapy, or chemotherapy plus G-CSF where tumour reduction or a high yield is needed (EBMT Handbook 2024); after chemotherapy the Handbook gives the approved filgrastim dose as 5 micrograms/kg/day, often rounded up to 5 to 10 in practice. The US filgrastim label gives 10 micrograms/kg/day for at least 4 days before the first apheresis and until the last. In myeloma, the US lenalidomide label says mobilisation should occur within 4 cycles of a lenalidomide-containing therapy. Monitor blood CD34 from day 4 to 5 of G-CSF at the latest, or when leucocytes recover after chemotherapy; start apheresis above 20 CD34 cells per microlitre. The Handbook gives the minimum dose for one autologous transplant as 2 million CD34 cells per kg (optimal 2.5 to 5 million) and for an allogeneic transplant 4 million per kg of the recipient (optimal 5 to 8 million). Poor mobilisation (about 15% of patients): the Handbook recommends plerixafor below 10 CD34 cells per microlitre on days 4 to 5, considers it between 10 and 20, and uses it as rescue if the first apheresis yields under a third of the goal; the US label sets no count threshold: plerixafor is indicated with filgrastim in non-Hodgkin lymphoma and myeloma, started after 4 days of filgrastim and given about 11 hours before each apheresis for up to 4 days, at 0.24 mg/kg (or a fixed 20 mg at 83 kg or less), not above 40 mg a day; when creatinine clearance is 50 mL/min or less the dose is reduced by one third to 0.16 mg/kg (or a fixed 13 mg at 83 kg or less) and should not exceed 27 mg a day. Motixafortide is a US-labelled alternative in myeloma. Donors (allogeneic): fitness is assessed by a physician who is not the patient's treating physician (WMDA 3.22.3.1); pregnancy test and haemoglobinopathy risk assessment before mobilisation (FACT-JACIE B6.3.5, B6.3.6); mobilising agents given under experienced supervision (B6.3.4); a central venous catheter only in exceptional, documented circumstances (WMDA 8.05.2); a session of no more than 5 hours and no more than two consecutive sessions (Handbook); follow-up contact for at least 10 years (WMDA 9.02). Plerixafor is not approved for healthy donors, and the US filgrastim label says mobilisation in healthy donors is not an approved indication. Left upper abdominal or shoulder pain during G-CSF needs assessment for splenic enlargement or rupture (label).","asOf":"2026-11-17","links":[],"tags":[],"related":["hct-conditioning-and-engraftment-care","car-t-apheresis","apheresis-starting-material","g-csf-growth-factors","cd34","wmda","nmdp","anthony-nolan"],"cancers":[],"sections":[],"technologies":["autologous-stem-cell-transplant","allogeneic-hsct"],"targets":[],"drugs":["filgrastim","lenograstim","plerixafor","motixafortide"],"companies":[],"institutions":[],"pathways":[],"terms":["apheresis"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"simple":"You have an injection under the skin each day for a few days. It makes stem cells move from your bones into your blood. Then you sit by a machine for a few hours while it collects the stem cells and gives the rest of your blood back. Bone aches are common. Tell the team at once about pain under the left ribs or in the left shoulder.","domain":"cell-therapy-toxicity","setting":{"who":["doctor","nurse","pharmacist","patient-or-carer","multidisciplinary-team"],"where":["outpatient-clinic","chemotherapy-day-unit","ward","home"]},"population":"Adults being prepared for an autologous transplant (most often for myeloma or lymphoma), and healthy adult related or unrelated donors giving peripheral blood stem cells for someone else. Children as patients or donors follow paediatric protocols; only the Handbook's key points on child donors are given, under variants. Bone marrow harvest, cord blood and lymphocyte collection for CAR-T are not covered. The US filgrastim, plerixafor and motixafortide labels cover autologous collection only; the filgrastim label says its use to mobilise cells in healthy donors is not an approved indication. This page explains what the collection team does; the reader's own team's protocol comes first.","trigger":"A decision to collect peripheral blood stem cells: for a patient, once the transplant plan is made; for a donor, once selected for a specific patient and before any mobilising injection is given.","steps":[{"action":"For a donor, have fitness to donate assessed by a physician who is not the doctor looking after the patient","why":"This keeps the judgement about whether the donor is fit to donate separate from the care of the patient who is waiting for the cells.","source":"wmda-standards-2024","quote":"This examination must be performed or supervised by a physician who is not the primary treating physician overseeing the care of the patient.","grade":"Standard 3.22.3.1 (must)"},{"action":"In the 7 days before the first mobilising injection, do a pregnancy test for anyone who could be pregnant; before mobilisation, confirm that the risk of a haemoglobin disorder such as sickle cell disease has been assessed, with testing if indicated","why":"A pregnancy must be known about before any mobilising medicine is given. The filgrastim label warns that severe and sometimes fatal sickle cell crises can occur in people with sickle cell disorders given G-CSF.","source":"fact-jacie-2025","quote":"The donor shall be evaluated for the risk of hemoglobinopathy and, if indicated, tested.","grade":"Standard B6.3.6 (shall)"},{"action":"For a patient, consider G-CSF alone when no further chemotherapy is needed; prefer chemotherapy followed by G-CSF when the tumour still needs reducing or a large number of cells is needed","why":"G-CSF alone has fewer side effects, a predictable collection day and can be given as an outpatient, but fails more variably and yields fewer cells; adding chemotherapy collects more cells and treats the cancer but brings the side effects of chemotherapy.","source":"ebmt-handbook-2024","quote":"Steady-state mobilization should be considered for patients who are not in need for chemotherapy due to the underlying disease (e.g., MM) or disease status (i.e., stable remission)."},{"action":"Give mobilising agents under the supervision of a clinician experienced in using them and in managing their complications","why":"The filgrastim label lists bone pain, fever and headache as the most common side effects of mobilisation and warns of serious ones, so the person in charge needs to know what to look for.","source":"fact-jacie-2025","quote":"Administration of mobilization agents shall be under the supervision of a licensed health care professional experienced in the administration of these agents and management of complications in persons receiving them.","grade":"Standard B6.3.4 (shall)"},{"action":"Give filgrastim by injection under the skin (10 micrograms per kg a day on the US label) for at least 4 days before the first collection and continue it until the last","why":"Stem cells need several days of growth factor to reach the blood in useful numbers, and the injections carry on so the numbers hold up through the collection days.","source":"neupogen-label","quote":"Administer NEUPOGEN for at least 4 days before the first leukapheresis procedure and continue until the last leukapheresis.","grade":"Prescribing information, section 2.3"},{"action":"Tell the person to report pain in the left upper abdomen or left shoulder straight away, and assess for an enlarged or ruptured spleen if it occurs","why":"The spleen can enlarge during G-CSF and has ruptured, in some cases fatally; the label lists pain in the left upper abdomen or left shoulder as the symptoms and asks that they be reported immediately.","source":"neupogen-label","quote":"Evaluate patients who report left upper abdominal or shoulder pain for an enlarged spleen or splenic rupture.","grade":"Prescribing information, section 5.1"},{"action":"Start measuring CD34 cells in the blood no later than day 4 to 5 of G-CSF alone, or when the white count recovers to 1000 per microlitre after mobilising chemotherapy","why":"The Handbook calls the CD34 count in the blood before apheresis the most robust predictor of poor mobilisation, and says the peak after chemotherapy is hard to predict without daily counts.","source":"ebmt-handbook-2024","quote":"If not otherwise specified by the protocol, CD34 monitoring should be initiated at the latest if leukocytes increase up to 1000 μL during recovering from aplasia or at day 4–5 of G-CSF in steady-state mobilization."},{"action":"Start apheresis once the blood CD34 count is above 20 cells per microlitre","why":"The Handbook counts people who bring fewer than 20 CD34 cells per microlitre into the blood as poor mobilisers, for whom it says plerixafor should be considered.","source":"ebmt-handbook-2024","quote":"A start of leukapheresis is indicated when a CD34+ cell count of >20/μL is reached (Mohty et al. 2014)."},{"action":"Set the collection target before starting, by the type of transplant, the stem cell source and the disease: at least 2 million CD34 cells per kg for one autologous transplant, and at least 4 million per kg of the recipient's weight for an allogeneic one","why":"Enough stem cells are needed for the blood counts to recover reliably after high-dose treatment.","source":"ebmt-handbook-2024","quote":"The target number of HSC to be collected is dependent among others on the kind of transplant (e.g., autologous or allogeneic), the stem cell source (BM or PB), and the underlying disease (Table 16.2)."},{"action":"In a person with myeloma who may have a transplant and is on lenalidomide, collect stem cells within the first 4 cycles","why":"The lenalidomide label reports fewer CD34 cells collected after more than 4 cycles. For people already past that point, or who collect too few with G-CSF alone, it says G-CSF with cyclophosphamide or with a CXCR4 inhibitor such as plerixafor may be considered.","source":"revlimid-label","quote":"For patients who are auto-HSCT-eligible, hematopoietic stem cell mobilization should occur within 4 cycles of a REVLIMID-containing therapy","grade":"Prescribing information, section 2.1"},{"action":"If more than one transplant may be needed, as in some people with myeloma, collect enough for all of them before the first high-dose treatment","why":"The Handbook says mobilisation after high-dose treatment has an increased risk of failure, so a later collection cannot be relied on.","source":"ebmt-handbook-2024","quote":"In these cases, it is essential to collect the required number of HSC before the first high-dose therapy since mobilization after high-dose therapy has an increased risk of failure."},{"action":"In a patient whose CD34 count is below 10 per microlitre on day 4 to 5 of G-CSF alone, add plerixafor; consider it between 10 and 20","why":"Plerixafor releases stem cells into the blood by a different route from G-CSF, and the Handbook says a second attempt with G-CSF after a failure is usually less effective. Between 10 and 20 the Handbook leaves the decision to the disease and the treatment history.","source":"ebmt-handbook-2024","quote":"Plerixafor is recommended when the CD34+ is <10/μL on days 4–5 of mobilization with G-CSF alone."},{"action":"If the first apheresis collects less than a third of the target, add plerixafor as rescue","why":"The Handbook says a first collection this low carries a high risk that mobilisation will fail.","source":"ebmt-handbook-2024","quote":"Furthermore, if it is not possible to collect at least one-third of the collection goal with the first apheresis session, plerixafor should be applied as a rescue strategy because of high risk of mobilization failure (Mohty et al. 2014; Cheng et al. 2015)."},{"action":"Give plerixafor under the skin about 11 hours before each apheresis, for up to 4 consecutive days, at the label dose for the person's weight and kidney function","why":"The label gives an evening dose before the next day's collection, with filgrastim each morning. Its dose is 0.24 mg per kg (or a fixed 20 mg at 83 kg or less), not more than 40 mg a day. When creatinine clearance is 50 mL/min or less it is cut by one third to 0.16 mg per kg (or a fixed 13 mg at 83 kg or less) and should not exceed 27 mg a day.","source":"mozobil-label","quote":"Administer Mozobil approximately 11 hours prior to initiation of each apheresis for up to 4 consecutive days.","grade":"Prescribing information, section 2.1"},{"action":"Collect through veins in the arms where possible; in a donor use a central venous catheter only in exceptional circumstances and record why","why":"The Handbook says collection is preferentially through a vein in the arm, with a central line where necessary; the WMDA standards also require a policy that protects the safety of a donor who has one.","source":"wmda-standards-2024","quote":"The registry must have a policy concerning the use of a central venous catheter in donors to ensure that a central venous catheter is only used in exceptional circumstances. Those circumstances must be documented.","grade":"Standard 8.05.2 (must)"},{"action":"Keep a donor's apheresis session to no more than 5 hours and to no more than two consecutive sessions; in patients, stop after three consecutive sessions","why":"These are the limits the Handbook sets for donors. For patients it says more than three consecutive sessions are futile in most cases, and that the goal is unlikely to be reached if it has not been by the third.","source":"ebmt-handbook-2024","quote":"In the allogeneic setting, the duration of one leukapheresis session should not exceed 5 h and two consecutive sessions."},{"action":"Have a written plan for a donor who does not mobilise enough cells, including whether to switch to a bone marrow collection","why":"The standard asks for the fallback to be written down in advance, as part of the policies that protect the health and safety of the donor and of the recipient.","source":"wmda-standards-2024","quote":"These policies must include the procedure to follow in case of failed mobilisation, including the potential to switch to a bone marrow collection if necessary.","grade":"Standard 8.05.1 (must)"},{"action":"Follow donors up straight after donation and keep a route open for them to report health concerns for at least ten years","why":"The standards require care for any condition related to the donation, straight afterwards and in the long term, and a way for the donor to raise a concern years later.","source":"wmda-standards-2024","quote":"The registry must have policies and procedures for the long-term follow-up and care of donors for conditions related to the HSC donation, including a mechanism for donors to contact the registry to report related medical concerns for a minimum of ten (10) years after donation.","grade":"Standard 9.02 (must)"}],"bestInClass":{"statement":"Donor safety has the firmest footing: the requirements here are 'must' and 'shall' standards of the World Marrow Donor Association (2024) and FACT-JACIE (ninth edition, version 9.1), which registries and transplant programmes are accredited against. For mobilising patients there is no single graded guideline that could be read in full. The steps follow the EBMT Handbook (2024), a handbook of expert chapters that draws on the EBMT position statement of 2014, with doses and timings from the manufacturers' labels. Two positions on plerixafor are shown side by side: the Handbook's count-guided use (added only when the blood CD34 count or the first collection is low) and the US label, which sets no count threshold and starts plerixafor after 4 days of filgrastim in people with non-Hodgkin lymphoma or myeloma. On lenalidomide the US label and the IMWG consensus of 2009 (abstract) agree that cells should be collected within the first 4 cycles. The American guidance of 2014 (ASBMT) could be read as abstracts only, which state no thresholds or targets, so its positions on CD34 targets and pre-emptive plerixafor are not shown; this is a named gap, not agreement.","sources":["wmda-standards-2024","fact-jacie-2025","ebmt-handbook-2024","ebmt-mobilisation-2014","mozobil-label","neupogen-label","revlimid-label","imwg-mobilisation-2009"]},"variants":[{"name":"Plerixafor for everyone, or only when counts are low","differs":"The US label, written for people with non-Hodgkin lymphoma or myeloma, sets no blood count threshold for starting plerixafor: \"Initiate Mozobil treatment after the patient has received filgrastim once daily for 4 days.\" The count-guided ('pre-emptive' or 'just-in-time') approach in the EBMT Handbook adds it only below a blood CD34 threshold or after a poor first collection.","evidence":"The Handbook: \"If a patient has below 20 CD34+ cells/μL, plerixafor application should be considered.\" Between 10 and 20 it leaves the decision to disease and treatment history, and for people with known risk factors for poor mobilisation says pre-emptive use should be considered. It reports that plerixafor reduces the number of apheresis sessions needed and so the cost of mobilisation. The EBMT 2014 abstract supports measuring the CD34 count before apheresis to allow pre-emptive intervention; its full text could not be read, and its medical writing was funded by a grant from the maker of plerixafor.","sources":["mozobil-label","ebmt-handbook-2024","ebmt-mobilisation-2014"]},{"name":"Chemotherapy with G-CSF rather than G-CSF alone","differs":"Gives a dose of chemotherapy (often cyclophosphamide 2 g per square metre, or the person's planned lymphoma chemotherapy) followed by G-CSF, with daily CD34 counts as the blood recovers, instead of G-CSF alone.","evidence":"The Handbook's key point: \"Mobilization with chemotherapy plus G-CSF is the preferred method for patients who will need decrease of tumor burden or who have to collect a high number of HSC.\" It lists the costs as chemotherapy toxicity, a hospital stay in most cases, marrow damage that may impair later mobilisation and higher cost, says relapse rates are comparable between the two strategies, and that 4 g per square metre of cyclophosphamide adds toxicity over 2 g.","sources":["ebmt-handbook-2024"]},{"name":"Motixafortide instead of plerixafor in myeloma","differs":"A newer injection, 1.25 mg per kg under the skin, given once 10 to 14 hours before the first apheresis after 4 days of filgrastim, with a possible second dose before a third apheresis. The label requires premedication before every dose.","evidence":"US label only: \"APHEXDA is indicated in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma.\" The label's safety data come from 92 patients given motixafortide and 42 given placebo, each with filgrastim, in the GENESIS study. It reports anaphylactic shock in 0.7% of patients given motixafortide in clinical studies and injection site reactions in 73% in GENESIS, and tells prescribers to premedicate every patient with an H1-antihistamine, an H2 blocker and a leukotriene inhibitor, to add a painkiller such as paracetamol, and to give it only where anaphylaxis can be treated at once. No guideline read compares it with plerixafor, and the EBMT Handbook chapter (2024) does not mention it.","sources":["aphexda-label"]},{"name":"Collecting after lenalidomide or daratumumab in myeloma","differs":"Collects early in induction, and plans for plerixafor or chemotherapy with G-CSF in people who have had more than 4 cycles of lenalidomide or a daratumumab-containing induction.","evidence":"The US lenalidomide label: \"A decrease in the number of CD34+ cells collected after treatment (> 4 cycles) with REVLIMID has been reported.\" It asks for early referral to a transplant centre, and says that after more than 4 cycles, or after an inadequate collection with G-CSF alone, G-CSF with cyclophosphamide or with a CXCR4 inhibitor may be considered. The IMWG consensus of 2009 (abstract only) recommends mobilisation \"preferably within the first 4 cycles of initial therapy\" for people treated with novel agents. The Handbook lists lenalidomide and daratumumab among the risk factors for poor mobilisation and says people given daratumumab in induction needed plerixafor significantly more often; it gives no number of cycles. The US daratumumab label says nothing about mobilisation.","sources":["revlimid-label","imwg-mobilisation-2009","ebmt-handbook-2024"]},{"name":"Collecting more than the minimum, and large-volume apheresis","differs":"Some centres aim for the Handbook's optimal range (2.5 to 5 million CD34 cells per kg for an autologous transplant) and process more than four times the person's blood volume in a session.","evidence":"The Handbook says higher yields have been associated with faster blood count recovery, shorter hospital stay and fewer transfusions, and advises: \"It may be advantageous to collect cells in this range, if the mobilization status of the patient allows it without additional leukapheresis session.\" For allogeneic grafts it also reports a study in which very high doses went with more extensive chronic graft-versus-host disease (62% against 34% at 4 years above and below 8.3 million per kg, sibling transplants).","sources":["ebmt-handbook-2024"]},{"name":"Plerixafor in healthy donors who mobilise poorly","differs":"Adds plerixafor to G-CSF for a donor whose CD34 count stays low, outside the licence.","evidence":"The Handbook: \"The use of plerixafor is not approved for allogeneic SCT.\" It puts mobilisation failure in healthy donors at an estimated 5% to 10% and cites studies in which adding plerixafor raised CD34 cells about three-fold. The WMDA standards require a failed-mobilisation procedure, including a possible switch to marrow collection, and do not name a drug. The WMDA published a separate statement on plerixafor in healthy donors in 2026, which could not be read; its position is not given here. The US filgrastim label adds that mobilisation in healthy donors is not an approved indication for filgrastim either, and reports bleeding into the lungs in donors.","sources":["ebmt-handbook-2024","wmda-standards-2024","mozobil-label","neupogen-label","wmda-plerixafor-donors-2026"]},{"name":"Children and others who cannot consent as donors","differs":"A child may be asked to donate for a brother or sister, which no adult volunteer standard covers in full.","evidence":"FACT-JACIE: \"A donor advocate shall be available to represent allogeneic donors who are minors or who do not have the capacity to give consent, as those terms are defined by Applicable Law.\" The EBMT Handbook's paediatric chapter: \"Minors should only be recruited as HSC donors if no medically equivalent histocompatible adult is available for donation and if there is a reasonable likelihood that the recipient will benefit from the procedure.\" It adds that donors under 4 years have a higher risk of complications, including from central line placement before apheresis.","sources":["fact-jacie-2025","ebmt-handbook-2024"]}],"grades":[{"claim":"Donor fitness examined or supervised by a physician independent of the patient's care","grade":"Standard 3.22.3.1 (must)","source":"wmda-standards-2024"},{"claim":"Pregnancy test and counselling before mobilising agents for donors of childbearing potential","grade":"Standard 3.22.3.2 (must)","source":"wmda-standards-2024","quote":"Female donors of childbearing potential must have a pregnancy test and be counselled to avoid pregnancy during the workup stage before use of mobilising agents, collection or initiation of the recipient’s preparative regimen, whichever occurs first."},{"claim":"Upper age for unrelated donors selected to donate should not exceed 60 years","grade":"Standard 3.16.1 (should)","source":"wmda-standards-2024","quote":"The upper age limit for prospective donors selected to donate haematopoietic stem cells should not exceed sixty (60) years."},{"claim":"Rationale for central venous access in a donor to be documented","grade":"Standard C6.3.10 (shall)","source":"fact-jacie-2025","quote":"If central venous access is required, the rationale shall be documented in the donor’s records."},{"claim":"Mobilisation appropriate to the disease and the donor","grade":"Standard B6.3.4.1 (shall)","source":"fact-jacie-2025","quote":"Appropriate mobilization shall be used for the disease being treated and for the donor being collected."},{"claim":"Plerixafor 'clearly indicated' below 10 CD34 cells per microlitre","grade":"Handbook advice (ungraded)","source":"ebmt-handbook-2024","quote":"Below 10 CD34+ cells/μL, the use of plerixafor is clearly indicated to avoid mobilization failure."},{"claim":"Measuring the blood CD34 count before apheresis identifies people at risk of a poor collection and allows pre-emptive rescue","grade":"Position statement (ungraded; abstract)","source":"ebmt-mobilisation-2014","quote":"Determination of the CD34+ cell count in PB before apheresis helps to identify patients at risk of poor PBSC collection and allows pre-emptive intervention to rescue mobilisation in these patients."},{"claim":"Plerixafor is licensed (US) with filgrastim for autologous collection in non-Hodgkin lymphoma and myeloma","grade":"Prescribing information, section 1","source":"mozobil-label","quote":"Mozobil is indicated in combination with filgrastim to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma (NHL) or multiple myeloma (MM)."},{"claim":"Plerixafor dose by weight (US label)","grade":"Prescribing information, highlights and section 2.1","source":"mozobil-label","quote":"Less than or equal to 83 kg: 20 mg dose or select dose based on 0.24 mg/kg actual body weight."},{"claim":"Plerixafor dose reduced by one third in moderate and severe renal impairment (US label)","grade":"Prescribing information, highlights and section 2.3","source":"mozobil-label","quote":"Renal impairment: If creatinine clearance is ≤50 mL/min, decrease dose by one-third to 0.16 mg/kg."},{"claim":"Filgrastim 10 micrograms per kg a day under the skin for mobilisation (US label)","grade":"Prescribing information, section 2.3","source":"neupogen-label","quote":"The recommended dosage of NEUPOGEN for the mobilization of autologous peripheral blood progenitor cells (PBPC) is 10 mcg/kg/day given by subcutaneous injection."},{"claim":"Filgrastim is not approved (US) for mobilisation in healthy donors","grade":"Prescribing information, section 5","source":"neupogen-label","quote":"The use of NEUPOGEN for PBPC mobilization in healthy donors is not an approved indication."},{"claim":"Collect early, preferably within the first 4 cycles, after novel agents in myeloma (IMWG 2009)","grade":"Consensus (ungraded; abstract)","source":"imwg-mobilisation-2009","quote":"Specifically, we recommend early mobilization of stem cells, preferably within the first 4 cycles of initial therapy, in patients treated with novel agents and encourage participation in clinical trials evaluating novel approaches to stem cell mobilization."},{"claim":"Filgrastim is licensed (US) for mobilising autologous progenitor cells","grade":"Prescribing information, section 1","source":"neupogen-label","quote":"NEUPOGEN is indicated for the mobilization of autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis"},{"claim":"An optimal mobilisation regimen has not been defined (ASBMT 2014)","grade":"Guideline abstract (grades not read)","source":"asbmt-duong-2014","quote":"However, an optimal stem cell mobilization regimen has not been defined."}],"sources":[{"key":"wmda-standards-2024","label":"2024 WMDA Standards (international standards for unrelated haematopoietic stem cell donor registries)","publisher":"World Marrow Donor Association","year":2024,"url":"https://wmda.info/wp-content/uploads/2024/01/2024-WMDA-Stnds_20240101-final.pdf","gradingScheme":"Accreditation standards, not graded evidence: each is worded 'must' (required) or 'should' (recommended).","read":"full-text","accessed":"2026-11-17"},{"key":"fact-jacie-2025","label":"FACT-JACIE International Standards for Hematopoietic Cellular Therapy Product Collection, Processing, and Administration, Ninth Edition, version 9.1","publisher":"Foundation for the Accreditation of Cellular Therapy (FACT) and JACIE (ISCT and EBMT)","year":2025,"url":"https://www.ebmt.org/sites/default/files/2025-12/FACT-JACIE%20HCT%20Standards%209th%20Ed_V9-1.pdf","gradingScheme":"Accreditation standards, not graded evidence: 'shall' means the standard is to be complied with at all times; 'should' is recommended or advised, with possible effective alternatives.","read":"full-text","accessed":"2026-11-17"},{"key":"ebmt-handbook-2024","label":"The EBMT Handbook: Hematopoietic Cell Transplantation and Cellular Therapies, 8th edition, chapter 16 (Mobilization and Collection of HSC) and chapter 17 (children)","publisher":"EBMT (Springer; Sureda, Corbacioglu, Greco, Kröger and Carreras, editors). A handbook of expert chapters, not a graded guideline","year":2024,"url":"https://www.ncbi.nlm.nih.gov/books/NBK608238/","doi":"10.1007/978-3-031-44080-9_16","gradingScheme":"None: the chapters give their authors' advice and cite the studies behind it.","read":"full-text","accessed":"2026-11-17"},{"key":"ebmt-mobilisation-2014","label":"Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation","publisher":"EBMT (Bone Marrow Transplantation, Mohty et al.). Medical writing funded by an unrestricted grant from Sanofi (industry)","year":2014,"url":"https://doi.org/10.1038/bmt.2014.39","doi":"10.1038/bmt.2014.39","gradingScheme":"Expert position statement; no grades in the abstract.","read":"abstract","accessed":"2026-11-17"},{"key":"asbmt-duong-2014","label":"Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation","publisher":"Biology of Blood and Marrow Transplantation (Duong et al.)","year":2014,"url":"https://doi.org/10.1016/j.bbmt.2014.05.003","doi":"10.1016/j.bbmt.2014.05.003","read":"abstract","accessed":"2026-11-17"},{"key":"asbmt-giralt-2014","label":"Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations","publisher":"Biology of Blood and Marrow Transplantation (Giralt et al.)","year":2014,"url":"https://doi.org/10.1016/j.bbmt.2013.10.013","doi":"10.1016/j.bbmt.2013.10.013","read":"abstract","accessed":"2026-11-17"},{"key":"wbmt-related-donors-2015","label":"Suitability Criteria for Adult Related Donors: A Consensus Statement from the Worldwide Network for Blood and Marrow Transplantation Standing Committee on Donor Issues","publisher":"Biology of Blood and Marrow Transplantation (Worel et al.)","year":2015,"url":"https://doi.org/10.1016/j.bbmt.2015.08.009","doi":"10.1016/j.bbmt.2015.08.009","read":"abstract","accessed":"2026-11-17"},{"key":"neupogen-label","label":"NEUPOGEN (filgrastim) injection: US prescribing information (manufacturer's label)","publisher":"Amgen (industry), on DailyMed, US National Library of Medicine","year":2026,"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97cc73cc-b5b7-458a-a933-77b00523e193","gradingScheme":"A regulator-approved label; not graded.","read":"full-text","accessed":"2026-11-17"},{"key":"mozobil-label","label":"MOZOBIL (plerixafor) injection: US prescribing information (manufacturer's label)","publisher":"Sanofi (industry), on DailyMed, US National Library of Medicine","year":2025,"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0ed08d2b-5051-46b2-aa37-1d6275bf9003","gradingScheme":"A regulator-approved label; not graded.","read":"full-text","accessed":"2026-11-17"},{"key":"aphexda-label","label":"APHEXDA (motixafortide) for injection: US prescribing information (manufacturer's label; text revised 9/2023, DailyMed version of 15 October 2026)","publisher":"BioLineRx (industry), on DailyMed, US National Library of Medicine","year":2026,"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f7cdc584-ebf0-a68e-e053-6294a90a9ea9","gradingScheme":"A regulator-approved label; not graded.","read":"full-text","accessed":"2026-11-17"},{"key":"revlimid-label","label":"REVLIMID (lenalidomide) capsules: US prescribing information (manufacturer's label; text revised March 2023, DailyMed version 41)","publisher":"Celgene Corporation (industry), on DailyMed, US National Library of Medicine","year":2023,"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5fa97bf5-28a2-48f1-8955-f56012d296be","gradingScheme":"A regulator-approved label; not graded.","read":"full-text","accessed":"2026-11-17"},{"key":"imwg-mobilisation-2009","label":"Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens","publisher":"International Myeloma Working Group (Blood, Kumar et al.)","year":2009,"url":"https://doi.org/10.1182/blood-2009-04-205013","doi":"10.1182/blood-2009-04-205013","gradingScheme":"Expert consensus; no grades in the abstract.","read":"abstract","accessed":"2026-11-17"},{"key":"wmda-plerixafor-donors-2026","label":"World Marrow Donor Association Statement on the Use of Plerixafor in Healthy Donors","publisher":"World Marrow Donor Association (Transplantation and Cellular Therapy)","year":2026,"url":"https://doi.org/10.1016/j.jtct.2026.01.021","doi":"10.1016/j.jtct.2026.01.021","read":"not-reachable","accessed":"2026-11-17"}],"upgrades":[],"gaps":["The American guidance (ASBMT guidelines, Duong 2014, and the consensus of Giralt 2014) could be read as abstracts only, and the abstracts give no CD34 target and no plerixafor threshold. Where the American and European positions differ on targets or on pre-emptive plerixafor is therefore not shown on this page. On 17 November 2026 the publisher's PDF link for the ASBMT guideline returned 403, and a search of Europe PMC found no newer ASTCT, EBMT, EHA or IMWG guideline on mobilisation; national consensus papers from Spain, France, Turkey and China (2017 to 2020) exist and were not read.","The EBMT position statement of 2014, which the Handbook cites for the start-of-apheresis threshold and the minimum dose, was read as an abstract only, again on 17 November 2026. Its medical writing was funded by a grant from the maker of plerixafor.","No source read grades its recommendations on mobilising patients: the Handbook is expert advice and the labels are manufacturers' documents. The count thresholds (10 and 20 CD34 cells per microlitre) are consensus figures.","The European product information for plerixafor, filgrastim and lenograstim was not read; licensed indications and doses are given from the US labels and, for European doses of filgrastim and lenograstim, from the Handbook. No US prescribing information for lenograstim as a mobilising agent was found on DailyMed. The Handbook's doses after chemotherapy (filgrastim 5 micrograms/kg/day, lenograstim 150 micrograms per square metre a day) are European approved doses as the Handbook reports them, not read from the product information.","Related (family) donors are outside the WMDA registry standards. The Worldwide Network consensus on related donors who would not qualify as unrelated donors (2015) was read as an abstract only, so its criteria are not given. The WMDA published recommendations on related donors handled by unrelated donor registries in 2026 (Transplantation and Cellular Therapy); no abstract was available and they were not read.","Motixafortide appears only in its own label; no guideline or handbook read places it against plerixafor. The European product information for motixafortide was not looked for.","Daratumumab-containing induction for myeloma is reported in the Handbook to increase the need for plerixafor; how to adapt mobilisation to it is not settled by any source read, and the US daratumumab label says nothing about it. The rule of collecting within 4 cycles of lenalidomide rests on the US label and on the abstract of the IMWG consensus of 2009, whose full text was not read; no source read says how many cycles of a daratumumab-containing induction should come before collection.","Calcium replacement during apheresis, citrate reactions, vein assessment and the day-of-collection nursing checks were not found in a guideline that could be read and are not written as steps. The CAR-T apheresis protocol covers some of the same ground for lymphocyte collection.","The WMDA standards read are the 2024 edition, which the WMDA standards page still offered on 17 November 2026; WMDA's separate donor medical suitability recommendations were not read. The WMDA statement on the use of plerixafor in healthy donors (2026) could not be read on 17 November 2026: there is no abstract in Europe PMC or Crossref and the publisher's page gave a script nothing. It may change what this page says about plerixafor for donors.","The EBMT Handbook was read from NCBI's open-access archive package because the publisher's site and the Bookshelf web pages refused a script. Crossref lists no update to the 8th edition (2024). The chapter says nothing about calcium, citrate or the nursing checks on the day, and it does not mention motixafortide."]},"route":"/protocols/stem-cell-mobilisation-and-collection/","neighbours":{"protocol":[{"id":"car-t-apheresis","kind":"protocol","name":"Leukapheresis to collect T cells for CAR T-cell manufacture","route":"/protocols/car-t-apheresis/"},{"id":"hct-conditioning-and-engraftment-care","kind":"protocol","name":"Stem cell transplant: conditioning, the low blood count phase and engraftment monitoring","route":"/protocols/hct-conditioning-and-engraftment-care/"}],"technology":[{"id":"allogeneic-hsct","kind":"technology","name":"Allogeneic stem cell transplantation","route":"/technologies/allogeneic-hsct/"},{"id":"apheresis-starting-material","kind":"technology","name":"Apheresis and starting-material collection","route":"/technologies/apheresis-starting-material/"},{"id":"autologous-stem-cell-transplant","kind":"technology","name":"Autologous stem cell transplant (high-dose therapy)","route":"/technologies/autologous-stem-cell-transplant/"},{"id":"g-csf-growth-factors","kind":"technology","name":"Growth factors: G-CSF and febrile neutropenia prevention","route":"/technologies/g-csf-growth-factors/"}],"target":[{"id":"cd34","kind":"target","name":"CD34","route":"/targets/cd34/"}],"institution":[{"id":"anthony-nolan","kind":"institution","name":"Anthony Nolan","route":"/institutions/anthony-nolan/"},{"id":"nmdp","kind":"institution","name":"NMDP","route":"/institutions/nmdp/"},{"id":"wmda","kind":"institution","name":"World Marrow Donor Association (WMDA)","route":"/institutions/wmda/"}],"drug":[{"id":"filgrastim","kind":"drug","name":"Filgrastim (G-CSF)","route":"/drugs/filgrastim/"},{"id":"lenograstim","kind":"drug","name":"Lenograstim","route":"/drugs/lenograstim/"},{"id":"motixafortide","kind":"drug","name":"Motixafortide","route":"/drugs/motixafortide/"},{"id":"plerixafor","kind":"drug","name":"Plerixafor","route":"/drugs/plerixafor/"}],"term":[{"id":"apheresis","kind":"term","name":"Apheresis (leukapheresis)","route":"/terms/apheresis/"}]}}